2Boden WE,OBourke RA,Teo KK,et al.COURAGE Trial Research Group.Optimal medical therapy with or without PCI for stable coronary disease.N Engl J Med,2007,356:1503-1516.
3Shaw LJ,Berman DS,Maron DJ,et al.COURAGE Investigntors.Optimal medical therapy with or without pereutsneous coronary intervention to reduce ischemie burden:results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.Circulation,2008,117:1283-1291.
4Jolly SS,Pogae J,Haladyn K,et al.Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention:insights from the PCI-CURE study.Eur Heart J.2009,30:900-907.
5Montalescot G.Sideris G,Meuleman C,et al.ALBION Trial Investigators.A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes:the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation,Inflammation and Ongoing Necrosis) trial.J Am Coll Cardiol,2006,48:931-938.
6Cuisset T,Frere C,Quilici J,et al.Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clihieal outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing comuary stenting.J Am Coll Cardiol,2006,48:1339-1345.
7Mehta SR,Baseand JP,Chrolavieias S,et al.CURRENT-OASIS 7 Steering Committee.Design and rationale of CURRENTOASIS 7:a randomized.2×2 factorial trial evaluating optimal dosing strategies for elopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy.Am Heart J,2008,156:1080-1088.
8Lagerqvist B,James SK,Stenestrund U,et al.SCAAR Study Group.Long-term outcomes with drug-eluting stents versus baremetal stents in Sweden.N Engl J Med,2007,356:1009-1019.
9James SK,Stenestrand U.Hndb(a)ck J,et al.SCAAR Study Group.Long-term safety and efficacy of drug-eluting versus baremetal stents in Sweden.N Engl J Med,2009,360:1933-1945.
10Taylor AJ,Sullenberger LE,Lee HJ,et al.Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2:a double-blind,placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.Cireulation,2004,110:3512-3517.
2Eric L Eisenstein, DBA,Kevin J. Anstrom, PhD,David F. Kong, MD,Linda K. Shaw, MS,Robert H. Tuttle, MSPH,Daniel B. Mark, MD, MPH,Judith M. Kramer, MD, MS,Robert A. Harrington, MD,David B. Matchar, MD,David E. Kandzari, MD 1,Eric D. Peterson, MD, MPH,Kevin A. Schulman, MD,Robert M. Califf, MD,李呈亿（译）,David E. Kandzari, MD.氯吡格雷的使用与药物洗脱支架植入后远期临床结果[J].美国医学会杂志（中文版）,2007,26(3):131-139. 被引量：59
5Kario K. Blood pressure variability in hypertension: a possible cardiovascular risk factor[J]. Am J Hypertens,2004,17(11 Pt 1) :1075-1076.
6Titapiccolo J I, Cerutti S, Garzotto F, et al. Blood pressure variability and cardiovascular autonomic control during hemodialysis in peripheral vascular disease patients[J]. Physiol Meas, 2012,33 (4): 667-678.
7Parati D, Ravogli A, Frattola A. et al. Blood pressure variability: clinical implication and effect of anti-hypertensive treatment[J]. J Hypertens, 1994,12(5) : 35-40.
8Rothwell P M, Howard S C, Dolan E, el al. Prognostic significance of visit to visit variability, maximum systolic blood pressure, and episodic hypertension[J]. Lancet, 2010, 375 (9718):895-905.
9Blaschke F, Bruemmer D, Yin F, et al. C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells[J]. Circulation,2004,110(5) : 579- 587.
